hit counter
Avadel Pharmaceuticals plc (AVDL) Stock News Sentiment & Price - Sentifly
AVDL - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Avadel Pharmaceuticals plc (AVDL)

Ireland
Biotechnology
NASDAQ
AVDL Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
AVDL Latest news
GlobeNewsWire
Neutral
Avadel Presents New Data Supporting Clinical Benefit with Once-at-Bedtime FT218 and Preference for Once-Nightly Dosing in Patients with Narcolepsy at CHEST 2021
2021-10-19 08:00

- Post-hoc responder analyses demonstrated a significantly greater proportion of patients receiving FT218 experienced reductions in weekly cataplexy attacks and improvement in mean sleep latency compared to placebo -

Newsfile Corp
Neutral
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avadel Pharmaceuticals plc - AVDL
2021-10-18 19:02

New York, New York--(Newsfile Corp. - October 18, 2021) -  Pomerantz LLP is investigating claims on behalf of investors of Avadel Pharmaceuticals plc ("Avadel" or the "Company") (NASDAQ: AVDL). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Avadel and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...

The Motley Fool
Negative
Why Shares of Avadel Are Sinking Today
2021-10-18 14:12

A key regulatory decision is overdue, leaving shareholders to wonder when it might arrive.

GlobeNewsWire
Neutral
Avadel Pharmaceuticals Announces Ongoing FDA Review of NDA for FT218 for Patients with Narcolepsy
2021-10-15 17:00

DUBLIN, Ireland, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that the U.S. Food and Drug Administration (FDA) notified the company that the review of the New Drug Application (NDA) for FT218 is still ongoing, and action will likely not be taken in October. The FDA informed the company that there are no information requests at this time and a new target action date will be provided as soon as possible.

Zacks Investment Research
Positive
Implied Volatility Surging for Avadel (AVDL) Stock Options
2021-09-29 10:30

Investors need to pay close attention to Avadel (AVDL) stock based on the movements in the options market lately.

GlobeNewsWire
Neutral
Avadel Pharmaceuticals Announces Publication of Data from Pivotal Phase 3 REST-ON Trial of FT218 in Adults with Narcolepsy in SLEEP
2021-08-16 08:00

DUBLIN, Ireland, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy, announced today the publication of data from its pivotal Phase 3 REST-ON trial of FT218 in SLEEP, the journal of the Sleep Research Society. The paper, titled “Once-Nightly Sodium Oxybate (FT218) Demonstrated Improvement of Symptoms in a Phase 3 Randomized Clinical Trial in Patients With Narcolepsy,” can be accessed at https://academic.oup.com/sleep/advance-article/doi/10.1093/sleep/zsab200/6343406?searchresult=1.

Seeking Alpha
Neutral
Avadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q2 2021 Results - Earnings Call Transcript
2021-08-09 12:39

Avadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q2 2021 Results - Earnings Call Transcript

GlobeNewsWire
Neutral
Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2021 Financial Results
2021-08-09 08:00

DUBLIN, Ireland, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy, today provided a corporate update and announced its financial results for the second quarter ended June 30, 2021.

Seeking Alpha
Neutral
Avadel Pharmaceuticals, The Jazz-Killer
2021-08-05 07:33

Avadel's once-nightly FT218 improves considerably over Xyrem's twice-nightly dosing.

GlobeNewsWire
Neutral
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2021 Financial Results on August 9th
2021-08-02 08:00

DUBLIN, Ireland, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company primarily focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, August 9, 2021, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2021.

Loading more news...